Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05977036 · ClinicalTrials.gov registry record · NA
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
A NA study of Metastatic Breast Cancer and Unresectable Breast Cancer, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT05977036 is a NA study of Metastatic Breast Cancer and Unresectable Breast Cancer that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 65 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05977036, a NA study of Metastatic Breast Cancer and Unresectable Breast Cancer, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with HR positive, HER-2 negative metastatic or unresectable breast cancer. Patients will receive first-line treatment with a CDK4/6 inhibitor (CDK4/6i) and endocrine therapy. All patients will have blood drawn for thymidine kinase activity (TKa) testing at baseline and at C1D15. Patients who are found to have a lack of TKa suppression at C1D15 will be recommended to switch to an alternative therapy. Patients with suppressed C1D15 TKa levels will continue on CDK4/6i and endocrine therapy until clinical progression. Patients with TKa which remains suppressed will be recommended to delay restaging scans from 24 weeks to 36 weeks. The investigators hypothesize that a patient's TKa level at C1D15 is prognostic for progression-free survival (PFS) on a CDK4/6 inhibitor and early therapeutic switching in patients with a lack of C1D15 TKa suppression will be associated with prolonged PFS.
Conditions Studied
Interventions
- DEVICE DiviTum® TKa assay
- DRUG CDK4/6 + Endocrine therapy
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2034-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05977036
The ClinicalTrials.gov registry entry for NCT05977036 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (68% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which DiviTum® TKa assay is the first listed.
NCT05977036 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT05977036 about?
NCT05977036 is a clinical study titled "BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer". This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with HR positive, HER-2 negative metastatic or unresectable breast cancer. Patients will receive fi...
What is the current status of trial NCT05977036?
This trial is currently recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2024-09-25. Estimated completion is 2034-09-30.
What conditions does trial NCT05977036 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Unresectable Breast Cancer.
What interventions are being tested in trial NCT05977036?
The interventions under investigation include: DiviTum® TKa assay (DEVICE), CDK4/6 + Endocrine therapy (DRUG).
Who is sponsoring clinical trial NCT05977036?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05977036 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptation of a Values Assessment Tool
RECRUITING · NA
-
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
RECRUITING · NA
-
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
RECRUITING · NA
-
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
RECRUITING · NA
-
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
RECRUITING · NA
-
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.